New in Orphan Drugs

Download Press Release: Shire Supports Rare Disease Day 2013

17 May 2013 / By jolene / Orphan Drugs, Uncategorized / 0 comments

On February 28 2013, at Lexington, Massachusetts, US, Shire announced its support of Rare Disease Day, joining patients, healthcare providers, and patient organisations around the [...]

 

More in Orphan Drugs

• 

  Orphan drug Kalydeco now available in Wales

  15 May 2013 / By Tim / Featured on app, Orphan Drugs / 0 comments

   
• 

  Vertex Kalydeco case: Identifying biomarkers to articulate the value of an orphan drug – Charles Johnson

  14 May 2013 / By Tim / Featured Videos, Featured on app, Orphan Drugs / 0 comments

   
• 

  The challenges and opportunities of first therapies in DMD – Claudia Hirawat

  14 May 2013 / By Tim / Featured Videos, Featured on app, Orphan Drugs / 0 comments

   
• 

  Guest blog: What do rare disease patients want from pharma?

  13 May 2013 / By Caroline Hornby / Orphan Drugs / 0 comments

   
• 

  Download Press Release: Shire Acquires Lotus Tissue Repair, Inc

  10 May 2013 / By jolene / Drug Discovery, Drug Safety, Orphan Drugs / 0 comments

   
• 

  Whitepapers: Challenges Faced in Rare Disease Product Development & The Role of a Patient Association

  8 May 2013 / By Matt Turner / Clinical Trials, Orphan Drugs, Partnering & Investment / 0 comments

   
• 

  Guest blog: The importance of patient advocates for orphan drugs

  6 May 2013 / By Caroline Hornby / Featured Videos, Orphan Drugs / 0 comments

   
• 

  Guest blog: Highlights from World Orphan Drug Congress USA 2013 by Siren Interactive

  6 May 2013 / By Caroline Hornby / Orphan Drugs / 0 comments

   
• 

  Download Shire’s Rare Disease Impact Report: Insights from patients and the medical community

  6 May 2013 / By jolene / Drug Discovery, Drug Safety, Orphan Drugs / 0 comments

   
• 

  Download presentation- Why transparency between stakeholders is essential when discussing pricing and reimbursement

  3 May 2013 / By Freya Smale / Orphan Drugs, Partnering & Investment / 0 comments